Biological Storage Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biological Storage Facility


Vindon’s UK storage suite based in Rochdale offers 2000 cubic meters of controlled environment storage space, providing pharmaceutical stability storage at all World Climatic ICH conditions as well as bespoke conditions.

Biological storage at low and ultra-low temperatures is available at temperatures from -20ºC to -80ºC. Vindon’s Ultra-low temperature facility can store millions of samples, vials or tube racks and annual validation and servicing by our in-house engineers ensures the most reliable storage solution.

Vindon’s HTA licensed Cryobank uses DryStore freezers for cryogenic storage at minus 190ºC, vapour phase storage systems designed to ensure against sample contamination. Our state of the art biorepository provides secure storage for stem cells, cord stem cells, biological samples, DNA and Bone Marrow.

Vindon Scientific also has IMB-certified storage facilities in Tramore, Ireland and storage suites in Kennesaw, near Atlanta, Georgia in the USA and from mid 2013 in Orange County, California, USA.

On-site engineers monitor equipment and undertake preventive maintenance with back-up generators providing additional security in the event of power failure.

Vindon engineers offer a full Validation and Calibration service using a combination of UKAS (United Kingdom Accreditation Service) calibrated equipment and state-of-the-art data acquisition systems, Vindon’s qualified and experienced engineers are extensively trained in the validation and calibration of any make/model of environmental chamber as well as our own Vindon manufactured product.

Vindon UK

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here